ES2673583T3 - Anticuerpo contra fibrina insoluble - Google Patents
Anticuerpo contra fibrina insoluble Download PDFInfo
- Publication number
- ES2673583T3 ES2673583T3 ES14757745.6T ES14757745T ES2673583T3 ES 2673583 T3 ES2673583 T3 ES 2673583T3 ES 14757745 T ES14757745 T ES 14757745T ES 2673583 T3 ES2673583 T3 ES 2673583T3
- Authority
- ES
- Spain
- Prior art keywords
- antibody
- fibrinogen
- chain
- fibrin
- present disclosure
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6843—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/745—Assays involving non-enzymic blood coagulation factors
- G01N2333/75—Fibrin; Fibrinogen
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/22—Haematology
- G01N2800/226—Thrombotic disorders, i.e. thrombo-embolism irrespective of location/organ involved, e.g. renal vein thrombosis, venous thrombosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2013039625 | 2013-02-28 | ||
| JP2013039625 | 2013-02-28 | ||
| PCT/JP2014/054925 WO2014133093A1 (ja) | 2013-02-28 | 2014-02-27 | 不溶性フィブリンに対する抗体 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2673583T3 true ES2673583T3 (es) | 2018-06-22 |
Family
ID=51428352
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES14757745.6T Active ES2673583T3 (es) | 2013-02-28 | 2014-02-27 | Anticuerpo contra fibrina insoluble |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US9429584B2 (enExample) |
| EP (2) | EP2963059B1 (enExample) |
| JP (2) | JP6490574B2 (enExample) |
| ES (1) | ES2673583T3 (enExample) |
| WO (1) | WO2014133093A1 (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016167227A1 (ja) * | 2015-04-13 | 2016-10-20 | 国立研究開発法人国立がん研究センター | 不溶性フィブリンに対する抗体 |
| JP2018527350A (ja) | 2015-09-01 | 2018-09-20 | イミュンワーク インク．Ｉｍｍｕｎｗｏｒｋ Ｉｎｃ． | 血餅形成の予防及び／又は血栓症の治療のための分子構築物 |
| UA126388C2 (uk) | 2016-11-18 | 2022-09-28 | Астеллас Фарма Інк. | Fab-фрагмент антитіла до muc1 людини |
| AU2017367734B2 (en) * | 2016-12-01 | 2025-01-09 | Regeneron Pharmaceuticals, Inc. | Radiolabeled anti-PD-l1 antibodies for immuno-PET imaging |
| BR112019016336A2 (pt) | 2017-02-10 | 2020-03-31 | Regeneron Pharmaceuticals, Inc. | Conjugado de anticorpo radiorrotulado, método para imageamento de um tecido que expressa lag3 e para tratar um tumor, e, composto. |
| SG11201910113PA (en) * | 2017-05-02 | 2019-11-28 | Nat Cancer Center Japan | Plasmin-cleavable anti-insoluble fibrin antibody-drug conjugate |
| TWI795415B (zh) * | 2017-07-07 | 2023-03-11 | 日商安斯泰來製藥股份有限公司 | 新穎的抗人類ＣＥＡＣＡＭ５抗體Ｆａｂ片段 |
| BR112020001360A2 (pt) | 2017-07-24 | 2020-08-11 | Regeneron Pharmaceuticals, Inc. | anticorpo monoclonal isolado ou fragmento de ligação a antígeno deste que se liga a cd8, composição farmacêutica, molécula de ácido nucleico, vetor de expressão, célula hospedeira, conjugado de anticorpo, métodos para gerar imagens de um tecido que expressa cd8, para tratar um sujeito tendo um tumor sólido, para prever uma resposta positiva a uma terapia antitumoral, para monitorar uma resposta de um tumor em um sujeito a uma terapia antitumoral, para prever ou monitorar a eficácia da terapia antitumoral e para monitorar a presença de células t em um tumor ao longo do tempo, e, composto. |
| WO2019221269A1 (ja) | 2018-05-17 | 2019-11-21 | アステラス製薬株式会社 | 抗ヒトＭＵＣ１抗体Ｆａｂフラグメント、ペプチドリンカー及び／又は配位子を含む複合体 |
| JP2022501428A (ja) * | 2018-09-17 | 2022-01-06 | アイカーン スクール オブ メディスン アット マウント シナイ | 抗ｌｉｌｒｂ２抗体およびその使用の方法 |
| SG11202103670XA (en) | 2018-10-10 | 2021-05-28 | Astellas Pharma Inc | Pharmaceutical composition containing tagged site-antihuman antibody fab fragment complex |
| WO2021163989A1 (en) * | 2020-02-21 | 2021-08-26 | Yinnuolai Biotech Ltd. | Anti-baff receptor antibodies and uses thereof |
| US12509507B2 (en) | 2020-03-31 | 2025-12-30 | National Cancer Center | Fusion protein suitable for dissolving fibrin clot, and pharmaceutical composition containing said fusion protein |
| CA3178880A1 (en) * | 2020-03-31 | 2021-10-07 | National Cancer Center | Fibrin-binding antibody and pharmaceutical composition containing antibody |
| EP3916009B1 (en) * | 2020-05-26 | 2023-06-28 | Sartorius Lab Instruments GmbH & Co. KG | Recombinant proteins based on fibrinogen |
| WO2023195535A1 (ja) | 2022-04-08 | 2023-10-12 | 株式会社凜研究所 | フィブリンに結合する抗体および当該抗体を含むフィブリン溶解性タンパク質および当該タンパク質を含む医薬製剤 |
| CN118240085B (zh) * | 2022-10-08 | 2025-05-09 | 东莞市朋志生物科技有限公司 | 抗纤维蛋白降解产物抗体、检测纤维蛋白降解产物的试剂和试剂盒 |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| US4916070A (en) | 1986-04-14 | 1990-04-10 | The General Hospital Corporation | Fibrin-specific antibodies and method of screening for the antibodies |
| US5120834A (en) * | 1988-06-13 | 1992-06-09 | American Biogenetic Sciences, Inc. | Fibrin-specific monoclonal antibody |
| IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
| EP1690935A3 (en) | 1990-01-12 | 2008-07-30 | Abgenix, Inc. | Generation of xenogeneic antibodies |
| DK0546073T3 (da) | 1990-08-29 | 1998-02-02 | Genpharm Int | Frembringelse og anvendelse af transgene, ikke-humane dyr, der er i stand til at danne heterologe antistoffer |
| WO1994025585A1 (en) | 1993-04-26 | 1994-11-10 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| JPH11206387A (ja) | 1991-08-28 | 1999-08-03 | Genpharm Internatl Inc | 異種免疫グロブリンを作る方法及びそのためのトランスジェニックマウス |
| US5648267A (en) | 1992-11-13 | 1997-07-15 | Idec Pharmaceuticals Corporation | Impaired dominant selectable marker sequence and intronic insertion strategies for enhancement of expression of gene product and expression vector systems comprising same |
| CU22615A1 (es) | 1994-06-30 | 2000-02-10 | Centro Inmunologia Molecular | Procedimiento de obtención de anticuerpos monoclonales murinos menos inmunogénicos. anticuerpos monoclonales obtenidos |
| AU701342B2 (en) | 1994-07-13 | 1999-01-28 | Chugai Seiyaku Kabushiki Kaisha | Reconstituted human antibody against human interleukin-8 |
| JPH11505107A (ja) | 1995-04-28 | 1999-05-18 | アブジェニックス インク． | 免疫したゼノマウス（ＸｅｎｏＭｏｕｓｅ）に由来するヒト抗体 |
| JPH08301900A (ja) | 1995-04-28 | 1996-11-19 | Shima Kenkyusho:Kk | 可溶性フィブリン複合体に対するモノクローナル抗体 |
| JPH09104700A (ja) | 1995-10-09 | 1997-04-22 | Bio Rinkusu Kk | 抗ヒト可溶性フィブリン抗体及びそれを用いた免疫学的測定法 |
| JP2001354700A (ja) | 2000-06-12 | 2001-12-25 | Bio Links Kk | モノクロ−ナル抗体及びヒトフィブリン分解産物の測定方法 |
| EP1345967B1 (en) | 2000-12-22 | 2011-08-10 | Grad, Carole, Legal representative of Kaplan, Howard | Phage display libraries of human v h fragments |
| WO2003000736A1 (en) | 2001-06-26 | 2003-01-03 | Agen Biomedical Limited | Humanized antibodies derived from dd-3b6/22, specific for the d-dimer fragment of fibrin |
| CA2594289A1 (en) | 2004-12-28 | 2006-07-06 | Daiichi Pure Chemicals Co., Ltd. | Anti-human soluble fibrin monoclonal antibody and immunological assay method using the antibody |
| JP5222521B2 (ja) | 2004-12-28 | 2013-06-26 | 積水メディカル株式会社 | 抗ヒト可溶性フィブリンモノクローナル抗体の製造方法 |
| KR101591206B1 (ko) * | 2005-12-12 | 2016-02-04 | 에이씨 이뮨 에스.에이. | 치료적 특성을 갖는 베타 1-42 특이적인 단일클론성 항체 |
| CA2642848C (en) * | 2006-03-03 | 2016-07-12 | Amorfix Life Sciences Ltd. | Methods and compositions to treat and detect misfolded-sod1 mediated diseases |
| JP5013378B2 (ja) | 2007-02-05 | 2012-08-29 | 国立大学法人大阪大学 | 新規ヘキサトリエン−β−カルボニル化合物 |
| EP2359852A4 (en) | 2008-11-17 | 2015-05-20 | Nat Cancer Ct | NEW CANCERED THERAPY WITH A SUBSTANCE COMPLEX SPECIFICALLY BINDING TO A TUMOR STREAM FACTOR AND ANTITUMIR COMPOUND |
| JP5805363B2 (ja) * | 2009-06-26 | 2015-11-04 | 和興フィルタテクノロジー株式会社 | 可溶性凝集体、免疫寛容誘導剤及びその製造方法 |
| JP2012000072A (ja) | 2010-06-18 | 2012-01-05 | Japan Health Science Foundation | 新規な抗フィブリン抗体 |
| AR086250A1 (es) * | 2011-05-05 | 2013-11-27 | Hoffmann La Roche | Polipeptido de fusion presentador de una secuencia de aminoacidos y utilizacion del mismo |
-
2014
- 2014-02-27 JP JP2015503025A patent/JP6490574B2/ja active Active
- 2014-02-27 ES ES14757745.6T patent/ES2673583T3/es active Active
- 2014-02-27 US US14/770,864 patent/US9429584B2/en active Active
- 2014-02-27 WO PCT/JP2014/054925 patent/WO2014133093A1/ja not_active Ceased
- 2014-02-27 EP EP14757745.6A patent/EP2963059B1/en active Active
- 2014-02-27 EP EP18155006.2A patent/EP3339327A3/en active Pending
-
2018
- 2018-07-23 JP JP2018137861A patent/JP7012360B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP2963059A4 (en) | 2017-03-22 |
| JP7012360B2 (ja) | 2022-02-14 |
| US20160011217A1 (en) | 2016-01-14 |
| EP2963059B1 (en) | 2018-04-04 |
| EP3339327A3 (en) | 2018-09-19 |
| JP2018193386A (ja) | 2018-12-06 |
| WO2014133093A1 (ja) | 2014-09-04 |
| EP2963059A1 (en) | 2016-01-06 |
| JP6490574B2 (ja) | 2019-03-27 |
| US9429584B2 (en) | 2016-08-30 |
| EP3339327A2 (en) | 2018-06-27 |
| JPWO2014133093A1 (ja) | 2017-02-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2673583T3 (es) | Anticuerpo contra fibrina insoluble | |
| US8101713B2 (en) | Prostate cancer diagnosis and treatment | |
| ES2657246T3 (es) | Procedimientos para tratar el cáncer pancreático | |
| ES2720594T3 (es) | Anticuerpos anti-fXI y métodos de uso | |
| BR112016011025B1 (pt) | Polipeptídeos anticorpo com especificidade de ligação para calicreina-2 humana (hk2), composição farmacêutica que os compreende e molécula de ácido nucleico | |
| ES2715279T3 (es) | Dominios variables individuales inmunoglobulínicos anti-receptor de manosa de macrófagos para elegir como diana y obtener imágenes in vivo de macrófagos asociados a tumores | |
| BRPI0908737B1 (pt) | Anticorpo, seu uso e método de diagnóstico de carcinoma hepatocelular | |
| US20230338589A1 (en) | In vivo immunoimaging of interferon-gamma | |
| Guan et al. | Polyethylene glycol-conjugated HER2-targeted peptides as a nuclear imaging probe for HER2-overexpressed gastric cancer detection in vivo | |
| TW201842938A (zh) | 可藉由胞漿素切斷之抗不溶性纖維蛋白抗體與藥物之複合體 | |
| WO2011158973A1 (ja) | 新規な抗フィブリン抗体 | |
| ES2709549T3 (es) | Métodos y composiciones farmacéuticas para el tratamiento de carcinomas hepatocelulares | |
| WO2025040093A1 (zh) | 靶向gpc3的分子探针以及用途 | |
| US6264949B1 (en) | Noninvasive agents for diagnosis and prognosis of the progression of fibrosis | |
| CN103201291A (zh) | 抗单链iv型胶原多肽抗体和包含其的用于诊断、预防或治疗肿瘤的药物或药剂 | |
| WO2016167227A1 (ja) | 不溶性フィブリンに対する抗体 | |
| EP3728301A2 (en) | Antibodies to centrin-1, methods of making, and uses thereof | |
| Matsumura | Cancer and blood coagulation | |
| TW202204411A (zh) | 與纖維蛋白結合之抗體及包含該抗體之醫藥組合物 | |
| WO2013141092A1 (ja) | 癌転移マーカー及びそれを用いた癌転移の診断方法 | |
| BR122020023278B1 (pt) | Uso de um polipeptídeo anticorpo para a fabricação de um medicamento para o tratamento e/ou diagnóstico de câncer de próstata |